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The peptide growth factor apelin is the high affinity ligand for the G-protein-coupled receptor APJ. During embryonic development of mouse
and frog, APJ receptor is expressed at high levels in endothelial precursor cells and in nascent vascular structures. Characterization of Xenopus
apelin shows that the sequence of the bioactive region of the peptide is perfectly conserved between frogs and mammals. Embryonic expression
studies indicate that apelin is expressed in, or immediately adjacent to, a subset of the developing vascular structures, particularly the
intersegmental vessels. Experimental inhibition of either apelin or APJ expression, using antisense morpholino oligos, results in elimination or
disruption of intersegmental vessels in a majority of embryos. In gain of function experiments, apelin peptide is a potent angiogenic factor when
tested using two in vivo angiogenesis assays, the frog embryo and the chicken chorioallantoic membrane. Furthermore, studies using the mouse
brain microvascular cell line bEnd.3 show that apelin acts as a mitogenic, chemotactic and anti-apoptotic agent for endothelial cells in culture.
Finally, we show that, similar to a number of other angiogenic factors, expression of the apelin gene is increased under conditions of hypoxia.
Taken together, these studies indicate that apelin is required for normal vascular development in the frog embryo and has properties consistent with
a role during normal and pathological angiogenesis.
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The first blood vessels in the embryo are formed by a process
called vasculogenesis, in which discrete vascular endothelial
precursor cells (angioblasts) assemble into a tubular vascular
plexus (Poole and Coffin, 1989; Cleaver and Krieg, 1998). All
subsequent growth of blood vessels into avascular tissues is
achieved through angiogenesis, which involves branching and
outgrowth of vessels from the initial vascular network. In the
frog embryo, the aortic arch vessels, posterior cardinal veins,
the dorsal aorta and the vitelline veins form through a
vasculogenic mechanism. The most prominent example of⁎ Corresponding author. Fax: +1 520 626 2097.
E-mail address: pkrieg@email.arizona.edu (P.A. Krieg).
0012-1606/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.04.452angiogenesis in the early embryo is the formation of the
intersegmental (or intersomitic) vessels, which branch from the
rudimentary posterior cardinal veins.
Numerous secreted growth factors play a regulatory role in
the growth and maintenance of blood vessels. For example,
vascular endothelial growth factor (VEGF-A) is a potent
mitogen for angioblasts and endothelial cells and gene ablation
experiments in mouse have demonstrated an absolute require-
ment for VEGF-A and its high affinity tyrosine kinase receptor
VEGFR-2 (flk-1) for embryonic vascular development (Carme-
liet et al., 1996; Ferrara et al., 1996; Shalaby et al., 1995). The
VEGF signaling pathway also plays an important role during
pathological growth of blood vessels. A large proportion of
human tumors express high levels of VEGF, and this expression
is directly related to their degree of vascularization and rate of
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reduction of VEGF signaling activity strongly correlates with
inhibition of tumor growth (Kim et al., 1993; Ferrara andAlitalo,
1999). The endothelial receptor tyrosine kinase Tie-2 (VEGFR-
1) and its high affinity ligands Angiopoietin-1 and 2 (Ang-1 and
Ang-2) are also required for embryonic vascular development
(Dumont et al., 1994; Sato et al., 1995; Suri et al., 1996), and the
extent of vascularization of tumors has also been correlated with
signaling via the Tie-2 pathway (Lin et al., 1997; Ahmad et al.,
2001; Shim et al., 2001; Oliner et al., 2004). A number of other
growth factor signaling pathways are capable of regulating
endothelial cell proliferation and function. In particular, several
G-protein-coupled receptor (GPCR) family members and their
cognate ligands are potent regulators of blood vessel growth.
Examples include, but are not limited to, stromal cell-derived
factor-1 (SDF-1) signaling through the CXCR4 receptor family
(Salvucci et al., 2004), sphingosine-1-phosphate (S1P) signaling
via the S1P(1–5) receptor family (Kluk and Hla, 2002) and
endocrine gland vascular endothelial growth factor (EG-VEGF)
which binds to the PKR1 and PKR2 receptors (Le Couter et al.,
2001; Lin et al., 2002).
The G-protein-coupled receptor, APJ (also named angioten-
sin II receptor-like 1—Agtrl1), was originally identified in a
survey for angiotensin-receptor-related sequences in the human
genome (O'Dowd et al., 1993). Subsequent experiments
however demonstrated that APJ does not bind angiotensin
and for a number of years the ligand required for APJ activity
remained unidentified. During early development, APJ expres-
sion is largely restricted to the endothelial cells and endothelial
precursor cells of the developing vasculature (Devic et al., 1996,
1999; Cleaver et al., 1997). In adult tissues, APJ transcripts are
present in a broad range of organs and tissue types including
lung, heart and kidney, and expression levels are particularly
high in neural tissues (O'Carrol et al., 2000). Additional studies
indicate that APJ is expressed on the surface of endothelial cells
throughout the adult vasculature (Katugampola et al., 2001)
suggesting a role for APJ-mediated signaling in maintenance or
modulation of vascular function.
A high affinity ligand for APJ, named apelin (APJ
endogenous ligand), has been isolated using biochemical
techniques (Tatemoto et al., 1998). Apelin mRNA encodes a
77-amino-acid preproprotein that is proteolytically cleaved to
yield bioactive peptides 36, 17 and 13 aa in size. Each of these
peptides contains the extreme C-terminal region of the precursor
protein, and all bioactivity is thought to reside in the terminal 13
aa fragment (Kawamata et al., 2001). There is evidence that
post-translational processing of apelin into the different peptide
isoforms is regulated in a tissue-specific manner (Kawamata et
al., 2001), but it has not been established whether the various
apelin isoforms possess distinct signaling properties or whether
differential processing of the precursor peptide is used to
regulate apelin activity. Since the identification of the apelin
ligand, experiments have implicated apelin/APJ signaling in
regulation of a number of physiological processes. For example,
studies using different model systems suggest that apelin may
regulate fluid uptake (Reaux et al., 2001; Taheri et al., 2002) and
food uptake (Taheri et al., 2002; Sunter et al., 2003; O'Shea etal., 2003), modulate blood pressure (Katugampola et al., 2001;
Tatemoto et al., 2001; Cheng et al., 2003; Ishida et al., 2004)
and function as a powerful regulator of cardiac contractility
(Szokodi et al., 2002; Chen et al., 2003; Berry et al., 2004). Still
other studies show that apelin and APJ are expressed during
formation of retinal vessels (Saint-Geniez et al., 2002, 2003),
and a recent report demonstrates that apelin possesses
angiogenic activity for a retinal endothelial cell line (Kasai et
al., 2004).
In this report, we show that apelin is required for normal
vascular patterning of the frog embryo. In addition, a variety of
in vivo and in vitro assays demonstrate that apelin is a powerful
stimulator of blood vessel growth and endothelial cell
proliferation. We provide evidence that these angiogenic
properties are independent of the VEGF signaling pathway.
The properties of apelin are consistent with a larger role in
regulation of blood vessel growth in the adult, under both
normal and pathological conditions.
Materials and methods
Recombinant DNA and peptides
Recombinants containing the frog (Xenopus) apelin preproprotein sequences
were identified in the expressed sequence tag (EST) database, GenBank
accession number BE680255. The Xenopus APJ recombinant construction (also
called X-msr) has been described previously (Devic et al., 1996; Cleaver et al.,
1997). Digoxygenin-labeled RNA probes for in situ hybridization were prepared
using a MegaScript kit (Ambion). Apelin peptide was synthesized to greater
than 90% purity (Sigma-Genosys). The N-terminal glutamine of native apelin
was modified to a pyroglutamic acid residue to avoid cyclization and poor yield
during the manufacturing process. Mutant apelin peptide, in which the final 4
residues were altered to alanine, was also synthesized.
Embryology and microinjection
Xenopus embryos were staged according to Nieuwkoop and Faber (1994).
For bead implantation experiments, Affi-gel blue beads (50–75 μm Bio-Rad)
were soaked in apelin peptide, mutant apelin peptide, BSA or recombinant
mouse VEGF-164 (R&D Systems) for 1 h on ice. Beads were implanted beneath
the epidermis in the posterior lateral region of stage 24–26 Xenopus embryos.
Embryos were cultured in 0.2× MMR until stage 34, at which time they were
fixed in MEMPFA. Whole mount in situ hybridization was carried out as
described previously (Harland, 1991). For apelin over-expression experiments,
approximately 500 pg of apelin mRNA was injected into one cell embryos,
together with 500 pg of EGFP mRNA as tracer. At the blastula stage, small
clumps of cells were isolated and implanted into the flank of stage 24 recipient
embryos. At stage 34, vascular structures were detected by in situ hybridization
using digoxygenin-labeled Xl erg probe (Baltzinger et al., 1999).
Loss-of-function experiments were performed using antisense morpholino
(MO) oligomers (Gene-Tools). Two antisense MOs overlapping the initiation
AUG were designed to block translation from both pseudoallelic copies of the
apelin transcript: apelin MO1 5′-GTGCCCAAAGTCTGAGATTCATGTT-3′,
apelin MO2 5′-GATTCATGTTTCTTGTGGCTGAGTG-3′. A 5-base mis-
match MO of apelin MO2 was called apelin MO2mut: 5′-GATT-
gATcTTTgTTGTGcCTcAGTG-3′. The mismatch nucleotides are shown in
lower case. For APJ, an MO was targeted immediately upstream of the
initiation AUG apj MO1: 5′-AAGGCTGTGTGGAAGCAATAGAAAG-3′. A
5-base mismatch control sequence for the apj MO1 was called apj MO1mut:
5′-AAGcCTcTGTGcAAcCAATAcAAAG-3′. MOs were injected (in 50 mM
HEPES pH 8.0) into one cell of the two-cell embryo, and the embryos were
allowed to develop until stage 35 at which time they were prepared for in situ
hybridization analysis. Texas Red Dextran (10 ng; Molecular Probes) was
coinjected with the MOs as a lineage tracer.
Fig. 1. Sequence alignment of mouse and Xenopus apelin preproproteins. Identical amino acids are indicated by asterisks. The vertical arrow indicates the position of
cleavage of the leader sequence. The open arrows mark the positions of post-translational proteolytic cleavage to generate 36, 17 and 13-mer forms of apelin. Note that
the sequence of the C-terminal bioactive region of the protein is perfectly conserved between frog and mouse. Mouse and Xenopus apelin preproprotein accession
numbers are BG176301 and BE680255 respectively.
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Chicken eggs were incubated at 37°C in a humidified chamber. On day 10 of
development, a window was made in the outer shell and a filter disk (3MMFig. 2. In situ hybridization analysis of APJ and apelin expression during Xenopus de
expression marks developing blood vessels throughout the embryo. The aortic arch re
branching intersegmental vessels (isv) are indicated. The region of expression in the
apelin expression is detected in the anterior region of the posterior cardinal vein, the ex
eye. Apelin expression is also detected in the ventral neural tube (nt). (C) At stage 35,
assembling vascular plexus in ventrolateral regions of the embryo and distinctly in
branching intersegmental vessels but expression in the vessels surrounding the eye is n
section through anterior trunk region of stage 32 embryo stained for apelin transcripts.
through trunk of stage 34 embryo stained for apelin. In addition to posterior cardinal v
ventral neural tube (nt). (G) Longitudinal section through ventral neural tube of stage
continuous but appears to mark paired motor neurons (Saha et al., 1997) (H).Whatman-8 mm diameter) carrying growth factor was placed onto the surface of
the CAM. Filter disks were pretreated with 0.1% cortisone acetate solution to
avoid inflammation of the CAM. After 3 days of incubation, the filter disks and
the attached CAM were excised, washed with PBS and photographed forvelopment. (A) In the Xenopus embryo at the early tailbud stage (stage 32) APJ
gion (aa) and the posterior cardinal vein (pcv), ventral vascular plexus (plex) and
tailbud does not appear to be associated with vascular tissue. (B) At stage 32,
tending intersegmental vessels and the developing blood vessels surrounding the
APJ transcripts are detected throughout the developing vasculature, including the
the intersegmental vessels. (D) At stage 35, apelin expression is visible in the
ow absent. No apelin transcripts are detected in the plexus region. (E) Transverse
Note prominent expression in the posterior cardinal veins. (F) Transverse section
eins, expression is visible in the hypochord (hc) and in paired regions within the
34 embryo stained for apelin. Anterior is to the left. Note that expression is not
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for different treatments was counted in a blinded analysis.
Cell culture and analysis
Mouse brain microvascular endothelial cells (bEnd.3; ATCC) were cultured
in DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin/
streptomycin (each 100 μg/ml; InVitrogen/Life Technologies). For proliferation
studies, bEnd.3 cells plated at 70% confluence in 8-well culture slides were
serum-starved for 24 h and then supplemented with growth factors for 24 h, after
which BrdU (10 μM) was added to each well for 2 h. In some experiments, FGF
receptor inhibitor (SU5402, 20 μM in DMSO) or VEGF receptor inhibitor
SU1498 (25 μM in DMSO) was added to the culture media for 1 h prior to
growth factor addition. BrdU analysis of cell proliferation was carried out as
follows: after BrdU incubation, cells were air-dried, rehydrated for 3 min with
PBS and then DNAwas denatured at 37°C with 2 M HCl and neutralized with
2 × 5 min washes of 0.1 M borate buffer (pH 8.5). Cells were washed 3 × 5 min
with PBS and blocked for 30 min in 1% normal goat serum/2% BSA. FITC-
labeled anti-BrdU antibody (10 μg/ml; Sigma) in block was added for 1 h at RT.
Cells were counter-stained with propidium iodide following several washes in
PBS. Three random fields from 3 wells were photographed for determination of
percentage BrdU labeling. Migration assays were performed using Trans-well
migration chambers with 8 μm pore size (Becton Dickinson). bEnd.3 cells were
plated in the upper chamber in the presence of 2% serum. Following cell
attachment to the membrane and overnight serum starvation, growth factor was
added to the bottom chamber for 6 h, after which cells that had migrated to the
lower chamber were fixed and stained with DAPI (1 μg/ml) for 30 min and then
counted. Apoptosis assays were carried out using the Promega Fluorescent
TUNEL kit and the protocol recommended by the manufacturer. Hypoxia assays
used primary rat cardiomyocytes and treatment for 4 h with 125 μM CoCl2, as
previously described (Chun et al., 2003).Results
Developmental expression of apelin and APJ
The apelin receptor APJ is expressed at high levels in
angioblasts and early vascular tissues of the Xenopus embryo
(Devic et al., 1996; Cleaver et al., 1997). In order to
investigate a possible role for apelin/APJ signaling during
vascular development, we have identified clones encoding
Xenopus apelin in the GenBank EST database. The deduced
amino acid sequence of Xenopus preproapelin is aligned to the
mouse protein in Fig. 1. Excluding the highly variable signal
peptide (residues 1–22), the mouse and frog apelin proproteins
are 51% identical overall, whereas the C-terminal 13 amino
acids, comprising the bioactive region of apelin, are identical
between the two species. The frog apelin precursor sequence
retains the proteolytic cleavage sites found in the mouse
preproprotein, suggesting that the previously characterized 36,
17 and 13 amino acid apelin isoforms will also be present in
the frog.
Using in situ hybridization, we have compared expression
of the APJ receptor and apelin ligand during Xenopus
embryonic development. Initial vascular expression of APJ
is detected in the frog embryo at approximately stage 28 in
angioblasts that will contribute to the posterior cardinal veins
and the aortic arch vessels (data not shown). At the early
tailbud stage (stage 32), expression of APJ is visible in
endothelial precursor cells in the aortic arch region, surround-
ing the eye, in the forming ventrolateral vascular plexus and inthe developing cardinal vein (Fig. 2A). A second non-
endothelial expression domain is also visible in the developing
tail. At approximately stage 32, about 8 h after initial APJ
receptor expression, apelin transcripts become visible in the
anterior region of the posterior cardinal vein and more
distinctly in vascular structures surrounding the developing
eye (Fig. 2B). Apelin expression is also visible in the dorsal
region of the embryo in posterior neural structures. Slightly
later in development (stage 35), APJ continues to be expressed
throughout developing vascular structures and staining
remains visible in the ventral vascular plexus. Strong
expression is also present in, or adjacent to, the endothelial
cells of the first intersegmental vessels that are branching from
the posterior cardinal vein (Fig. 2C). At this stage, apelin
expression has been lost from vessels surrounding the eye but
has become more pronounced in the intersegmental vessels
(Fig. 2D). Apelin expression is not observed in the aortic arch
region or in the ventral vascular plexus. Transverse sections
through a tailbud embryo show that apelin transcripts are
located in the endothelial cells of the posterior cardinal veins
(Fig. 2E). This tissue localization is unambiguous since there
are no smooth muscle cells associated with blood vessels at
this stage of Xenopus development. Slightly later (stage 34),
apelin transcripts are detected in the hypochord, a transient
embryonic structure located immediately ventral to the
notochord, and in paired regions within the ventral neural
tube (Fig. 2F). Longitudinal sections show that apelin is
expressed in individual cells on either side of the midline of
the neural tube (Fig. 2G), a pattern that is consistent with the
location of developing motor neurons (Saha et al., 1997).
Based on these expression patterns, we conclude that apelin is
expressed, either in immediate proximity to, or within, a
subset of the endothelial cells expressing the APJ receptor. We
also observe several expression domains of apelin, such as
hypochord and neural tissues that are not in immediate
proximity to APJ expressing cells. Note also that APJ is
expressed in the ventral vascular plexus and the extreme tip of
the developing tail, two domains that are not adjacent to
regions of apelin expression.
Apelin stimulates angiogenic growth in the frog embryo
The embryonic expression patterns of apelin and APJ
suggest that apelin may function to regulate vascular growth
or maintenance, at least within certain regions of the embryo.
We have tested this idea directly by implanting beads carrying
apelin peptide into the frog embryo and then assaying for
alterations in vascular patterning and growth. In these
experiments, agarose beads were soaked with different
concentrations of synthetic apelin(13) peptide, or mutant
apelin(13) peptide (in which the last 4 residues were altered
to alanine) and then inserted immediately below the epidermis
in the ventral posterior region of the frog embryo. This region
was selected because it is normally free of major vascular
structures. The bead implantation was carried out at stage 24–
26, prior to appearance of endothelial precursor cells in the
embryo, and was assayed by in situ hybridization with Xlerg
Table 1








1 mg/ml apelin 25/28 89
0.5 mg/ml apelin 8/9 89
0.25 mg/ml apelin 10/11 91
0.1 mg/ml apelin 7/7 100
1 mg/ml BSA 1/12 8
0.25 mg/ml mutant apelin 0/10 0
0.25 mg/ml VEGF 8/16 50
apelin expressing cell implants 12/12 100
EGFP expressing cell implants 0/9 0
Beads were implanted at stages 24–26 and cells at stage 24. At stages 34–35,
embryos were assayed for the presence of vascular tissue by in situ
hybridization using probe directed against transcripts for the endothelial marker
sequence erg.
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vascular network is normally present. Erg is a member of the ets
family of transcription factors and serves as an excellent
endothelial-specific marker in the frog embryo (Baltzinger et
al., 1999). As shown in Figs. 3A–C, the presence of a localized
source of apelin in the embryo stimulated a prominent
outgrowth of endothelial cells from the region of the posterior
cardinal vein towards the apelin bead. The effect was highly
reproducible using a range of concentrations of apelin peptide
(Table 1). Negative control experiments using beads soaked in
mutant apelin(13) never produced alterations to the vascular
structure (Fig. 3F and Table 1). Ectopic vascular structures were
also observed when cells injected with mRNA encoding apelin
preproprotein were implanted into the flank region of host
tadpoles (Figs. 3D, E and Table 1). This result demonstrates that
embryonic cells have the potential to process the apelin
precursor protein and to secrete apelin in a bioactive form. In
positive control experiments, agarose beads carrying VEGF
(165) stimulated outgrowth of endothelial cells towards the
source of VEGF (Fig. 3G and Table 1), similar to those
observed with apelin. In view of the importance of VEGF inFig. 3. Apelin is an angiogenic factor in the frog embryo. Porous beads treated with ap
into frog embryos at stages 24–26, and vascular structure was assayed by in situ hy
embryo showing location of apelin-soaked bead (arrow) and outgrowth of vascular tis
apelin bead. (D, E) Ectopic vascular cells in the vicinity of cell implants expressing a
mutated apelin peptide produces no ectopic marker expression. (G) A bead treated wi
hybridization analysis for VEGF transcripts shows that VEGF expression is not detec
the somites as previously reported (Cleaver et al., 1997).regulation of vascular growth, we considered the possibility that
apelin might function by locally upregulating expression of
VEGF in the embryo. If this is the case, then VEGF in theelin, control peptide or VEGF, or cells expressing apelin protein, were implanted
bridization using the vascular-specific erg marker at stage 34. (A) Whole frog
sue towards bead. (B, C) Enlarged views of vascular growth in the vicinity of the
pelin. Arrows indicate the position of the cell implants. (F) A bead soaked with
th VEGF(165) also produces vascular growth in the Xenopus embryo. (H) In situ
ted in the vicinity of the apelin bead 24 h after implantation but is detected within
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endothelial cell outgrowth documented in Table 1. To test this
possibility, we have assayed for VEGF expression around the
apelin bead, using in situ hybridization. In this experiment we
assayed for VEGF transcripts every 2 h (from 2 to 24 h) after
implantation of the bead. Although VEGF transcripts were
clearly detected in the somitic region of the embryo as
previously reported (Cleaver et al., 1997), no VEGF expression
was detected in the immediate vicinity of the apelin bead at any
time examined (Fig. 3H). Although preliminary, this result
suggests that apelin is not acting through upregulation of VEGF
expression.
Inhibition of apelin/APJ signaling using morpholino oligomers
alters vascular patterning in the frog embryo
To investigate whether apelin signaling is required for
embryonic vascular development, we have used morpholino
oligomers (MOs) to translationally inhibit the expression of
apelin and APJ. Two different MOs targeting apelin transcripts,
apelin MO1 and apelin MO2, were used in these studies. Both
MOs overlapped the initiation AUG, and both were shown to
inhibit translation of apelin mRNA in the frog embryo, using
methods previously described (Small et al., 2005, Fig. 4A). To
carry out the loss of function studies, 15 ng of apelin MO1 was
injected into one cell of the two-cell embryo. The uninjected
side of the embryo acts as a stage-matched control. At the
tailbud stage of development, vascular structures in the embryo
were visualized by in situ hybridization for erg transcripts. As
shown in Fig. 4, inhibition of apelin expression using apelin
MO1 generated a distinct alteration in vascular pattern on the
manipulated side of the embryo—specifically the reduction or
loss of intersegmental vessels (compare Figs. 4B and C).
Quantitation of the MO1 knockdown results showed that 67%
of embryos (51/76) exhibited distinct reduction in interseg-
mental vessel number on the injected side of the embryo. We
required that at least 3 intersegmental vessels be completely
absent before an embryo was scored as reduced. To confirm
these results with a different MO sequence, 7.5 ng of apelin
MO2 was injected into one cell of the two-cell embryo and the
resulting vascular pattern was assayed as described above.
Using MO2, 63% of injected embryos (40/64) showed a distinct
reduction in intersegmental vessel number (compare Figs. 4D
and E). A control MO containing 5-base mismatches relative to
apelin MO2 was injected at 15 ng per embryos (i.e. twice the
dose used for apelin MO2 experiments), and subsequent
analysis of vascular patterning showed that only 5% of embryosFig. 4. Antisense morpholino inhibition of apelin/APJ signaling in the frog embryo l
previously described (Small et al., 2005) to demonstrate effective inhibition of transla
upstream of the EGFP coding region. Fluorescence was visualized under UV illumina
two-cell embryo. The uninjected side of the embryo serves as a stage-matched contr
using probe for erg transcripts. (B, C) Control and injected side respectively of an em
intersegmental vessels on the MO-treated side (dashed arrows), while the majority
respectively of an embryo injected with a second apelin antisense MO (apelin MO2)
Control and treated side respectively of an embryo injected with APJ antisense MO
(dashed arrows). (H) Coinjection of APJ mRNA partially rescues intersomitic defects
statistically significant using the Chi-squared test.showed any reduction in intersegmental vessel number (2/38—
data not shown).
In order to determine whether loss of receptor showed the
same phenotype as loss of ligand, we used another MO (APJ
MO1) to inhibit expression of the APJ receptor. This MO was
demonstrated to inhibit APJ mRNA expression in control
experiments (Fig. 4A). Injection of 7.5 ng of APJ MO1 into one
cell of the two-cell embryo resulted in significant vascular
patterning defects when assayed at the tailbud stage of
development. As with the apelin knockdown experiments, the
most prominent defect was a reduction or loss of intersegmental
vessels on the injected side of the embryo (Figs. 4F, G).
Quantitation showed that 71% (34/48) of APJ-MO1-injected
embryos exhibited a significant reduction in the number of
intersegmental vessels. Injection of a mismatched APJ control
MO, at twice the experimental dose (15 ng), generated
intersegmental defects in only 14% of embryos (8/58—data
not shown). In some experiments, we also observed an apparent
reduction in endothelial cell number and disorganization of
structure in the region of the ventral plexus (see for example
Fig. 4G), but this was only observed in a small proportion of
cases. Finally, we demonstrate that coinjection of mRNA
encoding the APJ receptor was able to partially rescue the
vascular defects generated with APJ MO1 (Fig. 4H). Overall,
these inhibition experiments suggest a role for apelin/APJ
signaling in regulation of vascular patterning in the Xenopus
embryo, particularly in the growth of the intersegmental vessels.
Apelin stimulates angiogenesis in the chicken chorioallantoic
membrane (CAM) assay system
The chick CAM is an established in vivo model system for
assessment of angiogenic activity (Brooks et al., 1994; Ribatti et
al., 1995; 1997). We have carried out a series of experiments in
which filters soaked in control medium (PBS) or medium
supplemented with apelin or VEGF were placed in contact with
the CAM at approximately 10 days after fertilization. After 3
days of incubation, the degree of angiogenic stimulation was
assayed by counting the number of vascular branch points
(Wilting et al., 1991). Representative examples of control and
growth-factor-treated CAMs are shown in Figs. 5A–C.
Quantitation of the results of 3 separate experiments, each
including at least 7 individual CAMs, is presented in Fig. 5D.
These data show that apelin (10 ng/ml) stimulates angiogenic
branching approximately 2.5-fold relative to controls. The
stimulation of angiogenic growth is approximately equivalent to
that induced by treatment with VEGF (50 ng/ml).eads to vascular patterning defects. (A) Control experiments were carried out as
tion. Briefly, fusion transcripts contained 5′ UTR sequences of the target mRNAs
tion. (B–G) Embryos were injected with antisense morpholino into one cell of the
ol. In all cases, structure of vascular tissue was assayed by in situ hybridization
bryo treated with apelin antisense morpholino (apelin MO1). Note reduction in
of vascular structures appear to be unaffected. (D, E) Control and treated side
, again showing disruption of intersegmental vessels in the injected side. (F, G)
. Once again, growth of intersegmental vessels is disrupted on the injected side
generated using APJ MO1. Rescue with both 200 and 400 pg of APJ mRNA is
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Fig. 5. Apelin is an angiogenic factor in the chicken chorioallantoic membrane
(CAM) assay. (A) Photograph of CAM treated with buffer only. (B) Photograph
of representative CAM treated with VEGF and (C) representative CAM treated
with apelin. (D) Angiogenic activity was quantitated by counting the number of
vascular branch points resulting after each treatment. The bar indicates the
average of 3 different experiments, each counting at least 7 treated CAMs. The
standard error is indicated. Both VEGF and apelin stimulate approximately 2.5-
fold increase in angiogenic growth in the CAM assay.
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The results of in vivo studies described above suggest that
apelin stimulates proliferation and migration of vascular
endothelial cells, however, in the complex environment of
the embryo, it is very difficult to determine whether the
observed effects are direct or indirect. To specifically address
the effects of apelin signaling on endothelial cells, we have
carried out a number of studies using cells in culture. Primary
human umbilical vascular endothelial cells (HUVECs) are
commonly used for growth factor studies, but, in agreement
with a previous report (Kasai et al., 2004), we found that these
cells do not express detectable amounts of APJ. Examination
of a number of endothelial cells lines established that the
mouse brain microvasculature-derived endothelial cell line
bEnd.3 expressed significant amounts of the apelin receptor,
APJ, and the VEGF receptor, VEGFR-2 (data not shown), and
therefore we have used this cell line to investigate the
angiogenic properties of apelin/APJ signaling. Dose curves for
proliferation of bEnd.3 cells stimulated with VEGF(165) and
apelin(13) are presented in Fig. 6A. VEGF treatment at 10 ng/
ml increases bEnd.3 cell proliferation about 2-fold over serum-
free control levels, and this factor does not increase
significantly when the concentration of VEGF is raised to
100 ng/ml. Apelin treatment at 0.1 ng/ml produces a
significant increase in proliferation rate over serum-freecontrols (1.6-fold), and the rate of BrdU incorporation reaches
approximately 2-fold over control at 1 ng/ml. Increasing
apelin concentrations to 100 ng/ml does not produce any
further increase in cell proliferation. The monomeric apelin
(13) peptide has an MW of approximately 1.55 kDa, whereas
dimeric VEGF(165) has an MW of about 38 kDa. Based on
this 25-fold difference in mass, the dose curve in Fig. 6A
suggests that, in molar terms, apelin is almost as effective as
VEGF in stimulating endothelial cell proliferation. As a result
of these in vitro studies, it appears that the amounts of apelin
used in the embryonic bead implantation experiments (Fig. 3)
may have been much greater than necessary to elicit an
angiogenic response.
Apelin-induced cell proliferation is independent of VEGF and
FGF receptor signaling
Using cell proliferation as an assay, we have further
investigated whether apelin is a direct stimulator of angiogen-
esis or whether its effects may be mediated through
upregulation of other potent angiogenic growth factors,
specifically VEGF and FGF. To examine this possibility, we
have inhibited activity of the VEGF and FGF receptors using
the highly specific tyrosine kinase inhibitors SU1498 and
SU5402 respectively (Shen et al., 1999; Mohammadi et al.,
1997). As shown in Fig. 6B, addition of VEGF(165) at 50 ng/
ml stimulates bEnd.3 cell proliferation approximately 2.5-fold
over control levels, but this stimulation is reduced to almost
background levels when VEGF signaling is inhibited by
25 μM SU1498. In contrast, cell proliferation induced by
apelin at 10 ng/ml is not significantly inhibited by addition of
SU1498. This result suggests that apelin-stimulated cell
proliferation is not dependent on VEGF receptor function.
Similar experiments show that addition of bFGF at 50 ng/ml
increases bEnd.3 proliferation approximately 2-fold over
background levels and that this increase can be effectively
eliminated by co-treatment with the FGF receptor inhibitor
SU5402 at 20 μM. Once again, apelin stimulation of cell
proliferation is not significantly reduced in the presence of
SU5402. Taken together, these results indicate that the
mitogenic activity of apelin is not mediated via the VEGF
or FGF receptor pathways.
Apelin stimulates migration of endothelial cells and acts as an
anti-apoptotic agent
Using a standard trans-membrane migration assay in a
modified Boyden chamber, we have investigated the ability of
apelin to stimulate migration of endothelial cells. The results
show that apelin at 10 ng/ml stimulates bEnd.3 cell migration
approximately 2-fold over serum-free control levels (Fig. 7A).
This is approximately the same stimulation of migration as that
generated by VEGF (50 ng/ml). We have also investigated the
ability of apelin to inhibit programmed cell death (Fig. 7B).
Using a standard serum starvation protocol, our results illustrate
that supplementation of serum-free medium with apelin is able
to inhibit apoptosis (measured by TUNEL assay) to
Fig. 6. Apelin is a mitotic factor for endothelial cells in culture and acts independently of VEGF or FGF signaling. All studies were carried out using the mouse bEnd.3
cell line. (A) BrdU incorporation was used to assay proliferative response to different doses of apelin and VEGF(165). (B) SU1498 was used to inhibit VEGF/
VEGFR2-mediated proliferation. Note that SU1498 strongly inhibited VEGF-stimulated proliferation but did not significantly affect apelin-stimulated proliferation.
Apelin and VEGF were present at 10 ng/ml and 50 ng/ml respectively. (C) SU5402 was used to inhibit signaling through the FGF receptor. SU5402 strongly inhibited
FGF-stimulated proliferation of bEnd.3 cells but had no significant effect on apelin-stimulated proliferation. Apelin and bFGF were present at 10 ng/ml and 100 ng/ml
respectively. Panels show mean of 3 experiment plus SEM.
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procedure, VEGF at 50 ng/ml reduces apoptosis to about 30%
of control levels.
Apelin expression is induced by hypoxia in primary cardiac
myocyte cell culture
It has been noted that transcription of many angiogenic
growth factors is induced by low oxygen conditions (reviewed
in Wenger, 2002; Pugh and Ratcliffe, 2003). In order to provide
a thorough characterization of apelin as an angiogenic factor, wehave tested whether apelin transcription is activated in rat
cardiac myocytes treated with cobalt chloride (Ho and Bunn,
1996; Zhu and Bunn, 2001). Cobalt ions stabilize the hypoxia
inducible factor 1α (HIF-1α) transcription factor, thereby
activating the same transcription programs that are stimulated
by hypoxia (Ho and Bunn, 1996). Cardiac myocytes were used
for these experiments because they express significant levels of
apelin (Szokodi et al., 2002 and data not shown) and because
they have previously been demonstrated to activate angiogenic
gene expression in response to cobalt chloride treatment (Weil
et al., 2003; Chun et al., 2003). As shown in Fig. 7C, after 4 h of
Fig. 7. Apelin stimulates cell migration and is anti-apoptotic for endothelial
cells. Studies were carried out using mouse bEnd.3 cells. (A) A modified Trans-
well assay was used to measure growth-factor-mediated migration. Both VEGF
and apelin-stimulated migration approximately 2-fold over control levels. The
mean of 3 experiments plus SEM is shown. (B) Apoptosis was measured using
TUNEL assay after 3 days serum starvation. Both VEGF and apelin inhibit
apoptosis. The mean of 3 experiments plus SEM is shown. (C) Apelin
transcription is induced by treatment mimicking hypoxia. Real-time PCR
analysis of transcript levels following treatment of primary rat cardiomyocytes
with CoCl2 solution. Cytoskeletal β-actin was used as a normalization control,
and VEGF and GLUT1 are positive controls for hypoxia responsive genes.
Results of three different experiments, each in triplicate, plus SEM are shown.
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levels increased approximately twofold relative to cytoskeletal
β-actin transcripts. Expression of β-actin has previously been
shown to be unresponsive to hypoxia (Chun et al., 2003;
Vengellur and LaPres, 2004). For positive controls, we assayed
VEGF and GLUT1 transcripts, both of which are known to be
upregulated by hypoxia (Minchenko et al., 1994; Behrooz and
Ismail-Beigi, 1997). Under our experimental conditions, levelsof both transcripts were also increased about twofold (Fig. 7C).
Based on these experiments, we conclude that transcription of
apelin is increased under conditions of hypoxia and is regulated
by HIF-1α. This model is supported by the observation that
multiple HIF-1α binding sites are present in the promoter and
first intron of the apelin genes of mouse, chicken, zebrafish and
frog (data not shown). Although these experiments indicate
possible activation of apelin in hypoxia, we do not wish to
imply that hypoxia is involved in embryonic expression of
apelin in the developing vasculature.
Discussion
Developmental expression of apelin/APJ
The G-protein-coupled receptor APJ is expressed at high
levels in endothelial cells of the developing vasculature of frog
and mouse embryos (Devic et al., 1996; 1999; Cleaver et al.,
1997; Fig. 2). Analysis of apelin ligand expression (Fig. 2)
shows that apelin and APJ appear to be co-expressed in a
subset of endothelial cells in the Xenopus embryo, although
we cannot strictly exclude the possibility that apelin
expression occurs in cells adjacent to vascular structures
rather than endothelial cells themselves. This apparent co-
expression occurs in the developing posterior cardinal veins,
the vessels surrounding the eye and the branching interseg-
mental vessels. Apelin expression in at least some of these
domains is transient. For example, apelin is expressed in the
blood vessels dorsal to the eye at stage 32, but approximately
10 h later, at stage 35, apelin transcripts in this region are
undetectable. Apelin expression in the intersegmental vessels
is also strong but transient. The co-expression of apelin and
APJ in endothelial cells raises the possibility of autocrine
signaling during development of a subset of embryonic blood
vessels. It should be emphasized, however, that there are also
a significant number of examples where the apelin and APJ
expression domains are not coincident. For example, although
APJ is strongly expressed in the individual endothelial
precursor cells in the ventral plexus region and the aortic
arches (Fig. 2A), apelin expression is not observed at
significant levels in these regions. Similarly, although not
domains of vascular development, the ventral neural tube
expresses high levels of apelin (Figs. 2F, G), but no APJ
expressing cells are in the immediate vicinity. The lack of
overlap of apelin and APJ expression domains in some regions
of the embryo raises the possibility that additional ligands and/
or receptors may participate in the apelin/APJ signaling
pathway. Alternatively, given the ability of apelin to act as a
chemotactic agent for endothelial cells (Fig. 7A), the localized
sources of apelin in the embryo may help to regulate
angiogenic outgrowth into avascular tissues during subsequent
development.
Apelin/APJ signaling regulates Xenopus vascular development
We have tested for a developmental function for apelin/
APJ signaling using a morpholino knockdown strategy. These
187C.M. Cox et al. / Developmental Biology 296 (2006) 177–189experiments consistently yielded defects in development of
the intersegmental vessels. Identical phenotypes were
obtained when transcripts encoding either apelin (two MOs)
or the APJ receptor were targeted, suggesting that the
observed defects were specific and unlikely to be due to
generalized perturbations of normal embryonic development.
Somewhat surprisingly, other regions of the developing
vasculature appeared normal, implying that apelin/APJ
signaling is primarily involved in development of the
intersegmental vessels and not for other prominent vessels,
such as those surrounding the eyes, which also co-express
significant levels of apelin and APJ. Recently, APJ function
in the mouse has been ablated by homologous recombination
(Ishida et al., 2004). The mice are viable and fertile and show
no obvious defects in vascular development or function,
although the animals do exhibit increased vascular contrac-
tility in response to blood pressure regulators. At least two
explanations may account for the different results observed in
the frog and mouse loss of function studies. First, the mouse
may possess redundant signaling activities that are not present
in the frog embryo. These putative signaling molecules might
be an alternative to the APJ receptor that can bind the apelin
ligand or may represent an unrelated signaling pathway that
shares angiogenic activity. Indeed, the possibility of additional
signaling or receptor molecules is consistent with the
observed non-congruence of apelin and APJ expression
domains already noted in the frog embryo. Second, the
inhibition of intersegmental vessel growth observed in the
frog may be a transient effect that is corrected during later
development. In this interpretation, the mouse embryos may
also have exhibited early vascular defects, but these were not
evident at postnatal stages when the animals were studied.
Since MOs cease to be effective fairly early in frog
embryonic development (Heasman et al., 2000), it is not
possible to determine long-term knockdown effects using this
model system.
Apelin acts independently of VEGF signaling
We have used both frog embryos and chick CAM assays to
demonstrate that apelin possesses angiogenic activity in vivo. In
these experiments, apelin/APJ signaling may directly activate
endothelial cell migration and proliferation or it may be acting
through upregulation of another angiogenic factor. For example,
both thrombin and angiotensin II, signaling through the receptors
PAR-1 and AT-1R respectively, demonstrate angiogenic proper-
ties in vivo and in vitro, but at least a proportion of these activities
appear to be mediated through upregulation of the VEGF
signaling pathway (Richard et al., 2000; Williams et al., 1995).
Similarly, the growth factor TWEAK, acting through the Fn14
receptor, has been shown to potentiate the mitogenic activity of
FGF-2 andVEGF for endothelial cells (Donohue et al., 2003).We
have specifically addressed the question whether apelin exerts its
effects through upregulation of VEGF expression in the frog
embryo. In situ hybridization detection of VEGF transcripts
shows no detectable expression of VEGF in the vicinity of the
apelin bead (Fig. 3H), suggesting that apelin does not act viatranscriptional upregulation of VEGF activity. This general result
has been confirmed under more controlled conditions in
experiments using cultured cells. When VEGF signaling is
suppressed using the VEGFR2 kinase inhibitor SU1498, apelin-
stimulated proliferation of endothelial cells is not significantly
inhibited. Similarly, inhibition of FGF signaling using the
receptor tyrosine kinase inhibitor SU5402 does not result in
inhibition of cell division regulated by apelin. These studies do
not preclude the possibility that apelin activates expression of
other factors capable of stimulating endothelial cell division, but
the results suggest that such effects are not regulated via simple
upregulation of expression of VEGF-A or FGF family growth
factors.
G protein signaling and vascular function
In whole animal studies, apelin has been shown to regulate a
range of physiological activities including regulation of fluid and
food uptake, modulation of vascular tone and regulation of
heartbeat. Apelin therefore joins an intriguing group of GPCR
ligands that exhibit angiogenic properties and also a range of
other, apparently unrelated physiological activities. For example,
prokineticin-1 (also called EG-VEGF) is an 86 aa protein that
binds to the PK1 receptor and stimulates smooth muscle
contraction and is also a potent angiogenic agent (Le Couter et
al., 2001; Li et al., 2001). Angiotensin II is an 8 amino acid
peptide that possesses angiogenic properties and also regulates
physiological pathways that modulate blood pressure, fluid and
sodium retention and cardiac function (Touyz, 2003). Similarly,
adrenomedullin exhibits potent vasodilator and diuretic activity
(Brain and Grant, 2004) in addition to angiogenic properties
(Oehler et al., 2002). It seems reasonable to assume that the
angiogenesis-stimulating properties of these factors are not
directly related to their vasoregulatory roles under normal
physiological conditions. Our results show that apelin is a
mitogen for endothelial cells in vivo (Figs. 3, 5) and in vitro (Fig.
6) and that apelin possesses chemotactic activity for endothelial
cells (Fig. 7A) and is anti-apoptotic for endothelial cells in culture
(Fig. 7B). These data are in broad agreementwith a previous study
using mouse retinal endothelial cells (Kasai et al., 2004).
Furthermore, apelin expression is increased in cells cultured
under conditions mimicking hypoxia (Fig. 7C). This latter result
suggests that apelin expression may be upregulated during the
hypoxic conditions associatedwith early tumor growth (Folkman,
1995) and may have the ability to stimulate the growth or
stabilization of tumor blood vessels. Overall, our studies suggest
that apelin/APJ signaling is required for normal development of
the vascular system in the frog embryo. Furthermore, in addition
to its known functions in regulating heart and vascular
physiology, apelin has the potential to modulate normal and
pathological blood vessel growth in the mature organism.
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